Market closedNon-fractional

Aerovate Therapeutics/AVTE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Aerovate Therapeutics

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Ticker

AVTE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

51

AVTE Metrics

BasicAdvanced
$53M
Market cap
-
P/E ratio
-$3.03
EPS
1.39
Beta
-
Dividend rate
$53M
1.39
6.653
6.401
0.362
0.851
-47.78%
-80.58%
0.56
0.56
-0.721
30.48%
-59.55%

What the Analysts think about AVTE

Analyst Ratings

Majority rating from 7 analysts.
Buy

AVTE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$23M
13.24%
Profit margin
0.00%
NaN%

AVTE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.50%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.76
-$0.71
-$0.74
-$0.83
-
Expected
-$0.70
-$0.69
-$0.71
-$0.77
-$0.80
Surprise
9.20%
2.66%
4.57%
8.50%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aerovate Therapeutics stock?

Aerovate Therapeutics (AVTE) has a market cap of $53M as of July 23, 2024.

What is the P/E ratio for Aerovate Therapeutics stock?

The price to earnings (P/E) ratio for Aerovate Therapeutics (AVTE) stock is 0 as of July 23, 2024.

Does Aerovate Therapeutics stock pay dividends?

No, Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Aerovate Therapeutics dividend payment date?

Aerovate Therapeutics (AVTE) stock does not pay dividends to its shareholders.

What is the beta indicator for Aerovate Therapeutics?

Aerovate Therapeutics (AVTE) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Aerovate Therapeutics stock

Buy or sell Aerovate Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing